Anzeige
Mehr »
Login
Sonntag, 05.02.2023 Börsentäglich über 12.000 News von 679 internationalen Medien
Der Hot Stock für die KW 06: Meldungen überschlagen sich!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0JEGY ISIN: AU000000CUV3 Ticker-Symbol: UR9 
Tradegate
03.02.23
20:05 Uhr
15,900 Euro
-0,050
-0,31 %
Branche
Biotechnologie
Aktienmarkt
AUSTRALIEN
1-Jahres-Chart
CLINUVEL PHARMACEUTICALS LIMITED Chart 1 Jahr
5-Tage-Chart
CLINUVEL PHARMACEUTICALS LIMITED 5-Tage-Chart
RealtimeGeldBriefZeit
15,80516,12504.02.
15,85016,05003.02.

Aktuelle News zur CLINUVEL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoClinuvel Pharmaceuticals Limited: CLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned Individuals153MELBOURNE, Australia, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Results released today from a clinical study have shown that the drug afamelanotide can reduce critical skin damage caused by ultraviolet (UV)...
► Artikel lesen
DoCLINUVEL PHARMACEUTICALS LIMITED: Technical note - CUV151 results8
CLINUVEL Aktie jetzt für 0€ handeln
DoCLINUVEL PHARMACEUTICALS LIMITED: Afamelanotide reduces UV skin damage in a healthy population7
29.01.CLINUVEL PHARMACEUTICALS LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report94
23.01.CLINUVEL PHARMACEUTICALS LIMITED: NEURACTHEL manufacturing processes advance46
16.01.Clinuvel Pharmaceuticals Limited: CLINUVEL Trial Results Show Drug Reduces DNA Damage319MELBOURNE, Australia, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Results from a clinical trial in a genetic DNA repair disorder show that a new drug - afamelanotide - may be able to reduce the development...
► Artikel lesen
15.01.CLINUVEL PHARMACEUTICALS LIMITED: Technical Note - Xeroderma Pigmentosum4
15.01.CLINUVEL PHARMACEUTICALS LIMITED: afamelanotide Reduces DNA Photodamage in XP8
10.01.CLINUVEL PHARMACEUTICALS LIMITED: CLINUVEL Newsletter I - January 202337
23.12.22CLINUVEL PHARMACEUTICALS LIMITED: CLINUVEL Newsletter VI - December 202247
21.12.22CLINUVEL PHARMACEUTICALS LIMITED: Notification of cessation of securities - CUV24
15.11.22CLINUVEL PHARMACEUTICALS LIMITED: Presentation - Jefferies London Healthcare Conference32
07.11.22CLINUVEL PHARMACEUTICALS LIMITED: CLINUVEL Newsletter V - November 202226
07.11.22CLINUVEL PHARMACEUTICALS LIMITED: Change of Director's Interest Notice16
06.11.22Dr Boreham's Crucible: The Five-Year plan is complete - is Clinuvel finally ready for its time in the sun?24
31.10.22Why Clinuvel, Nitro, Premier Investments, and Pushpay shares are rising25
31.10.22CLINUVEL PHARMACEUTICALS LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report Re-issued29
26.10.22CLINUVEL PHARMACEUTICALS LIMITED: Results of Meeting17
26.10.22CLINUVEL PHARMACEUTICALS LIMITED: Chair Address6
21.10.22CLINUVEL PHARMACEUTICALS LIMITED: Melbourne Investor Briefing Presentation10
Seite:  Weiter >>
38 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
4,1,7